<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01529554</url>
  </required_header>
  <id_info>
    <org_study_id>CLEVER-ACS</org_study_id>
    <nct_id>NCT01529554</nct_id>
  </id_info>
  <brief_title>Controlled Level EVERolimus in Acute Coronary Syndromes</brief_title>
  <acronym>CLEVER-ACS</acronym>
  <official_title>Phase I-II Randomized Prospective Double-blind Multi-center Trial on the Effects of a Short Course of Oral Everolimus on Infarct Size, Left Ventricular Remodeling and Inflammation in Patients With Acute ST-Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myocardial infarction (AMI) constitutes the major cause of death in most nations and
      death rates and morbidity remain substantial in the years thereafter. Inflammation is a
      hallmark throughout the distinct stages of atherosclerotic lesion formation preceding AMI as
      well as at the time of plaque rupture and during the post-infarct repair phase. Harnessing
      its harmful consequences constitutes an attractive therapeutic approach to address this unmet
      medical need.

      The objectives of this study are to evaluate the effects of mTOR inhibition (everolimus) on
      infarct size, myocardial function and inflammation in patients with ST-Elevation Myocardial
      Infarction.

      The efficacy objectives are:

        1. (1° endpoint):

           To assess the effect of mTOR inhibition (everolimus) on myocardial infarct size as
           change from baseline (12-72 hours after percutaneous coronary intervention) to 30 days
           follow-up measured by MRI (Late Gadolinium Enhancement (LGE) for transmurality).

        2. (2° endpoint):

           To evaluate microvascular obstruction (MVO) as change from baseline (12-72 hours after
           percutaneous coronary intervention) to 30 days follow-up evaluated by MRI.

        3. (3° endpoints):

             1. Change of left ventricular volume from baseline (12-72 hours after percutaneous
                coronary intervention) to 30 days follow-up measured by MRI.

             2. Change of biomarkers from time of coronary angiography to 30 days follow-up
                including a time-course (AUC). Biomarkers comprise hs-TnT, NT-proBNP, hs-CRP, IL-6
                and inflammatory biomarkers OPG, sRANKL, OPN and CCN1.

      The safety objectives are:

      To explore the effect of mTOR inhibition (everolimus) on several clinical and safety
      laboratory parameters including plasma lipid levels and blood count. This will be
      complemented by analysis of inflammatory cell subsets in coronary thrombi and peripheral
      blood (CD4+ T helper lymphocyte subsets, monocyte subsets).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial infarct size measured by MRI</measure>
    <time_frame>Change from baseline at 30 days</time_frame>
    <description>To assess the effect of mTOR inhibition (everolimus) on myocardial infarct size as measured by MRI (Late Gadolinium Enhancement (LGE) for infarct size (transmurality) at 12-72 h (baseline) and 30 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microvascular obstruction (MVO) measured by MRI</measure>
    <time_frame>Change from baseline at 30 days</time_frame>
    <description>To evaluate microvascular obstruction (MVO) by MRI at 12-72 h (baseline) and 30 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Acute Coronary Syndromes</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everolimus p.o. for 5 days (d0=7.5 mg, d1=7.5 mg, d2=7.5 mg, d3=5 mg, d4=5mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator with identical composition of tablets except everolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>(d0=7.5 mg, d1=7.5 mg. d2=7.5 mg, d3=5 mg, d4=5mg)</description>
    <arm_group_label>Everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matched placebo tablets manufactured to be identical to verum tablets except content of everolimus</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Elevation Myocardial Infarction (STEMI) as defined by:

        ST-Elevation &gt; 1mm in &gt; 2 leads OR Novel left bundle branch block (LBBB) OR Posterior MI
        with ST-Depression &gt; 1mm in &gt; 2 leads Chest pain duration of &gt; 10 minutes Primary Coronary
        Intervention (PCI) with drug-eluting stent (DES) within 24 hours of chest pain onset in the
        occluded culprit artery First Myocardial Infarction Occluded coronary artery at angiography
        specifically occlusion of one coronary vessel in the proximal third of either LAD, RCX or
        RCA, the mid segment of right coronary artery (RCA) or mid segment of a large left anterior
        descending (LAD) coronary artery, i.e. when the latter reaches the apex.

        Male and female patients 18 years to 90 years of age Signed informed consent

        Exclusion Criteria:

        Participation in another drug or stent trial Pregnant women or nursing mothers Mechanical
        complication during acute coronary syndrome Scheduled PCI for additional lesion within 30
        days Multivessel disease Major elective surgery planned in trial period Malignancy (unless
        healed or remission &gt; 5 years) Chronic infection (HIV, Tbc, empyema) Severely compromised
        renal function (GFR&lt; 30 ml/min)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas F Luescher, Professor</last_name>
    <role>Study Director</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Denegri, MD</last_name>
    <phone>0041 44 255</phone>
    <phone_ext>9978</phone_ext>
    <email>andrea.denegri@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Windecker, Professor</last_name>
      <email>stephan.windecker@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Stephan Windecker, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Geneva</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Mach, Professor</last_name>
      <email>francois.mach@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Francois Mach, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiocentro Ticino</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiziano Moccetti, Professor</last_name>
    </contact>
    <contact_backup>
      <email>tiziano.moccetti@cardiocentro.org</email>
    </contact_backup>
    <investigator>
      <last_name>Tiziano Moccetti, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Denegri, MD</last_name>
      <phone>+41 44 255</phone>
      <phone_ext>99 78</phone_ext>
      <email>andrea.denegri@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Andrea Denegri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>February 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2012</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Coronary Syndromes</keyword>
  <keyword>ST-Elevation Myocardial Infarction</keyword>
  <keyword>Infarct size</keyword>
  <keyword>inflammation</keyword>
  <keyword>everolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

